Recent Updates
Recently added Catalysts
OCUL Positive Sentiment

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Key Takeaway: Ocular Therapeutix announced inducement grants to Tiffany Howard, its new EVP for Commercial – Retina. The awards include a stock option for 200,000 shares and a restricted stock unit for 65,000 shares, effective November 16, 2026. These grants are part of Ocular's 2019 Inducement Stock Incentive Plan and aim to attract talent to the company.

Market Sentiment Analysis

POSITIVE FACTORS

  • Inducement awards granted to new EVP Tiffany Howard.
  • Stock options and restricted stock units provided as incentives.
  • Company's commitment to retinal health emphasized.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
6.5%
average across 15 past catalysts
Cash runway
~24 mo
Low dilution risk
Lead asset
OTX-TKI
Phase 3 · Neovascular Age-related Macular Degeneration

Full Press Release Details

BEDFORD, Mass., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Tiffany Howard, the Company’s new Executive Vice President, Commercial – Retina. The awards were made as an inducement material to the recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity awards were granted effective as of November 16, 2026, and consist of a non-statutory stock option award to purchase up to 200,000 shares of Ocular’s common stock and a restricted stock unit award representing the right to receive 65,000 shares of Ocular’s common stock. The stock option award has an exercise price of $6.01 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. The stock option award has a ten-year term and vests over four years, with 25% of the original number of shares subject to the award vesting on the one-year anniversary of the date of grant, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. The restricted stock unit award vests over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates.
The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.
About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.
Follow the Company on its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media Ocular Therapeutix, Inc. Bill Slattery Vice President, Investor Relations bslattery@ocutx.com

Frequently Asked Questions

What inducement awards were granted to Tiffany Howard?

Tiffany Howard received a stock option for 200,000 shares and a restricted stock unit for 65,000 shares.

When were the inducement awards effective?

The inducement awards were effective as of November 16, 2026.

What is the exercise price for the stock option?

The exercise price for the stock option is $6.01 per share.

What is AXPAXLI?

AXPAXLI is Ocular's investigational product for retinal disease, currently in Phase 3 trials.

Last updated: Nov 20, 2026